Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218849 | 1.00 | EPHX1 (0.50) | EPHX1CYP2D6SRCDPP4F2 | |
| SCHEMBL544671 | 1.00 | EPHX1 (0.50) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137431 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL28645850 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137429 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Methane SCHEMBL6241814 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137441 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL27583753 | 0.95 | EPHX1 (0.47) | EPHX1CYP2D6SRCDPP4F2 | |
| Acetic Acid SCHEMBL27430362 | 0.93 | ALOX5 (0.46) | EPHX1CYP2D6SRCDPP4F2 | |
| SCHEMBL7193261 | 0.87 | PTGS2 (0.52) | DPP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| WO-2015022437-A1 | INDOLINONE DERIVATIVES AS GRK5 MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-02-19 | — | — | WO | claimed |
| WO-1990008126-A1 | RESOLUTION PROCESS | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1990-07-26 | — | — | WO | claimed |
| EP-4308168-B1 | METHODS FOR PREPARING CYCLOOCTENES AND CONJUGATES THEREOF | TAGWORKS PHARMACEUTICALS B V (NL) | 2026-05-20 | — | — | EP | disclosed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| CN-121627535-A | Deracemization method of phenylglycine amide | 天津大学 | 2026-03-10 | — | — | CN | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12344589-B2 | Method for producing a 1,5-benzothiazepin compound | ELOBIX AB (SE) | 2025-07-01 | — | — | US | disclosed |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119823023-A | Process for preparing functionalized cyclooctenes | 坦博公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113473975-B | Process for preparing functionalized cyclooctenes | 坦博公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-1046523-C | Process for making antimicrobial quinolonyl lactams | PROCTER & GAMBLE PHARMA (US) | 1999-11-17 | — | — | CN | disclosed |
| US-5801242-A | Process for making quinolonyl lactam antimicrobials and novel intermediate compounds | THE PROCTER & GAMBLE COMPANY (US) | 1998-09-01 | — | — | US | disclosed |
| US-5703231-A | Process for making antimicrobial compounds | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| CN-1159809-A | Process for making quinolonyl lactam antimicrobials and novel intermediate compounds | PROCTER & GAMBLE (US) | 1997-09-17 | — | — | CN | disclosed |
| CN-1158120-A | Process for the preparation of antimicrobial compounds | PROCTER & GAMBLE (US) | 1997-08-27 | — | — | CN | disclosed |
| CN-1075146-A | The method for preparing antimicrobial quinolonyl lactams | PROCTER & GAMBLE PHARMA (US) | 1993-08-11 | — | — | CN | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
| EP-0411074-A1 | RESOLUTION PROCESS | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1991-02-06 | — | — | EP | disclosed |
| WO-1990008126-A1 | RESOLUTION PROCESS | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1990-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | EPHX1 2634/4885CYP2D6 719/4885SRC 3285/4885 |
| US-12344589-B2 | Method for producing a 1,5-benzothiazepin compound | CYP3A5, KCNJ5, KCNK5 | EPHX1 1827/4885CYP2D6 193/4885SRC 4765/4885 |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | EPHX1 1595/4885CYP2D6 139/4885SRC 976/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | EPHX1 4802/4885CYP2D6 4475/4885SRC 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.